Visualitzant O - Articles científics per títol

Health-related quality of life associated with trifluridine/tipiracil in heavily pretreated metastatic gastric cancer: results from TAGS

Tabernero Caturla, Josep; Alsina Maqueda, Maria; Shitara, Kohei; Doi, Toshihiko; Dvorkin, Mikhail; Mansoor, Wasat (Springer, 2020-07)

Health-related quality of life in patients with a germline BRCA mutation and metastatic pancreatic cancer receiving maintenance olaparib

Hammel, Pascal; Kindler, H. L.; Reni, M.; Van Cutsem, Eric; Macarulla Mercadé, Teresa; Hall, Michael J (Oxford University Press, 2019-12)

Health-related quality of life in the phase III ASCENT trial of sacituzumab govitecan versus standard chemotherapy in metastatic triple-negative breast cancer

Loibl, Sibylle; Loirat, Delphine; Tolaney, Sara M; Punie, Kevin; Antunes de Melo Oliveira, Ana Mafalda; Rugo, Hope (Elsevier, 2023-01)

Health-related Quality of Life in the Phase III LUME-Colon 1 Study: Comparison and Interpretation of Results From EORTC QLQ-C30 Analyses

Lenz, Heinz-Josef; Argilés Martinez, Guillem; Falcone, Alfredo; Limón, María Luisa; Yoshino, Takayuki; Lonardi, Sara (Elsevier, 2019-12)

Health-Related Quality of Life with Pembrolizumab in Patients with Locally Advanced or Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma: KEYNOTE-629

Bratland, Åse; MORTIER, Laurent; Roshdy, Osama; González, Rene; Schachter, Jacob; MUÑOZ COUSELO, EVA (Springer, 2023-12)

Hepatic Rupture as the Initial Presentation of an EGFR-Mutated Lung Adenocarcinoma: A Case Report

Mirallas Viñas, Oriol; Pardo Aranda, Nuria; Aubanell, Anton; Salcedo Allende, Maria Teresa; Callejo Perez, Ana; Iranzo Gómez, Patricia; Tabernero Caturla, Josep; Felip Font, Enriqueta; Bosch Schips, Marc (Frontiers Media, 2022-03)

HER2 and p95HER2 differentially regulate miRNA expression in MCF-7 breast cancer cells and downregulate MYB proteins through miR-221/222 and miR-503

Gorbatenko, Andrej; Søkilde, Rolf; Sorensen, Ester E.; Newie, Inga; Persson, Helena; Morancho Armisen, Beatriz; Arribas López, Joaquin Vicente (Nature Publishing Group, 2019-03-04)

HER2 Copy Number and Resistance Mechanisms in Patients with HER2-positive Advanced Gastric Cancer Receiving Initial Trastuzumab-based Therapy in JACOB Trial

Manca, Paolo; Corso, Simona; Raimondi, Alessandra; Berrino, Enrico; Tabernero Caturla, Josep; Pietrantonio, Filippo; Bellomo, Sara Erika (American Association for Cancer Research, 2023-02-01)

HER2DX genomic test in HER2-positive/hormone receptor-positive breast cancer treated with neoadjuvant trastuzumab and pertuzumab: A correlative analysis from the PerELISA trial

DIECI, MARIA VITTORIA; Griguolo, Gaia; Marín-Aguilera, Mercedes; GUARNERI, VALENTINA; Brasó Maristany, Fara; Paré, Laia; Vivancos, Ana (Elsevier, 2022-11)

Hereditary Leiomyomatosis and Renal Cell Cancer Syndrome in Spain: Clinical and Genetic Characterization

Sánchez-Heras, A. Beatriz; Castillejo, Adela; García-Díaz, Juan D.; Teulé, Alexandre; Sánchez, Rosario; Lopez Fernandez, Adrià; Balmaña Gelpí, Judith; Robledo, Mercedes (MDPI, 2020-11-05)

HERTHENA-Lung01, a Phase II Trial of Patritumab Deruxtecan (HER3-DXd) in Epidermal Growth Factor Receptor–Mutated Non–Small-Cell Lung Cancer After Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and Platinum-Based Chemotherapy

yu, helena; Goto, Yasushi; Hayashi, Hidetoshi; FELIP, ENRIQUETA; Yang, James Chih-Hsin; Reck, Martin (American Society of Clinical Oncology, 2023-12-10)

HERTHENA-Lung01: a phase II study of patritumab deruxtecan (HER3-DXd) in previously treated metastatic EGFR-mutated NSCLC

Yu, Helena A; Hayashi, Hidetoshi; Goto, Yasushi; Reck, Martin; Yang, James Chih-Hsin; FELIP, ENRIQUETA (Future Medicine, 2023-06)

Hierarchical chromatin organization detected by TADpole

Soler-Vila, Paula; Cusco Pons, Pol; Farabella, Irene; Di Stefano, Marco; Marti-Renom, Marc A. (Oxford University Press , 2020-04-17)

High absolute lymphocyte counts are associated with longer overall survival in patients with metastatic breast cancer treated with eribulin—but not with treatment of physician’s choice—in the EMBRACE study

Miyoshi, Yasuo; Yoshimura, Yuta; Saito, Kenichi; Muramoto, Kenzo; Sugawara, Michiko; Alexis, Karenza; Cortés Castan, Javier (Springer, 2020-07)

High levels of chromosomal aberrations negatively associate with benefit to checkpoint inhibition in NSCLC

Iranzo Gómez, Patricia; Pardo Aranda, Nuria; Callejo Perez, Ana; Cedres Perez, Susana; Martínez Marti, Alexandre; Navarro Mendivil, Alejandro; Soleda, Mireia; Jiménez Flores, José Antonio; Hernandez Losa, Javier; Vivancos Prellezo, Ana; Felip Font, Enriqueta; Amat, Ramon; Carbonell, Caterina; Frigola Rissech, Joan (BMJ, 2022-04)

High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER+ breast cancer

Palafox Sánchez, Marta; Monserrat Vicente, Laia; Gonzalez-Perez, Abel; Antunes de Melo Oliveira, Ana Mafalda; Òdena, Andreu; Sanchez-Guixe, Monica; Capelan Rodríguez, Marta; Azaro Pedrazzoli, Analía Beatriz; Rodriguez Ferreiro, Olga; Guzman Torres, Marta; Grueso Gragera, Judit; Viaplana Donato, Cristina; Hernandez Losa, Javier; Arribas López, Joaquin Vicente; Nuciforo, Paolo Giovanni; Serra Elizalde, Violeta; Villacampa Javierre, Guillermo; Bellet Ezquerra, Meritxell; Saura Manich, Cristina; Dienstmann, Rodrigo (Nature Portfolio, 2022-09-07)

Scientia. Dipòsit d'Informació Digital del Departament de Salut

Visualitzant VHIO - Articles científics per títol

Health-related quality of life associated with trifluridine/tipiracil in heavily pretreated metastatic gastric cancer: results from TAGS

Health-related quality of life in patients with a germline BRCA mutation and metastatic pancreatic cancer receiving maintenance olaparib

Health-related quality of life in the phase III ASCENT trial of sacituzumab govitecan versus standard chemotherapy in metastatic triple-negative breast cancer

Health-related Quality of Life in the Phase III LUME-Colon 1 Study: Comparison and Interpretation of Results From EORTC QLQ-C30 Analyses

Health-Related Quality of Life with Pembrolizumab in Patients with Locally Advanced or Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma: KEYNOTE-629

Hepatic Rupture as the Initial Presentation of an EGFR-Mutated Lung Adenocarcinoma: A Case Report

HER2 and p95HER2 differentially regulate miRNA expression in MCF-7 breast cancer cells and downregulate MYB proteins through miR-221/222 and miR-503

HER2 Copy Number and Resistance Mechanisms in Patients with HER2-positive Advanced Gastric Cancer Receiving Initial Trastuzumab-based Therapy in JACOB Trial

HER2DX genomic test in HER2-positive/hormone receptor-positive breast cancer treated with neoadjuvant trastuzumab and pertuzumab: A correlative analysis from the PerELISA trial

Hereditary Leiomyomatosis and Renal Cell Cancer Syndrome in Spain: Clinical and Genetic Characterization

HERTHENA-Lung01, a Phase II Trial of Patritumab Deruxtecan (HER3-DXd) in Epidermal Growth Factor Receptor–Mutated Non–Small-Cell Lung Cancer After Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and Platinum-Based Chemotherapy

HERTHENA-Lung01: a phase II study of patritumab deruxtecan (HER3-DXd) in previously treated metastatic EGFR-mutated NSCLC

Hierarchical chromatin organization detected by TADpole

High absolute lymphocyte counts are associated with longer overall survival in patients with metastatic breast cancer treated with eribulin—but not with treatment of physician’s choice—in the EMBRACE study

High levels of chromosomal aberrations negatively associate with benefit to checkpoint inhibition in NSCLC

High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER+ breast cancer

Highlights from ASCO-GI 2021 from EORTC Gastrointestinal tract cancer group

Hitting the brakes on autophagy for overcoming acquired resistance in triple negative breast cancer

HMGA1, Moonlighting Protein Function, and Cellular Real Estate: Location, Location, Location!

Homologous Recombination Deficiency Across Subtypes of Primary Breast Cancer

Coneix Scientia

Guies i ajudes

Directe a...

Coneix Scientia

Guies i ajudes

Directe a...

Visualitzant VHIO - Articles científics per títol

Health-related quality of life associated with trifluridine/tipiracil in heavily pretreated metastatic gastric cancer: results from TAGS ﻿

Health-related quality of life in patients with a germline BRCA mutation and metastatic pancreatic cancer receiving maintenance olaparib ﻿

Health-related quality of life in the phase III ASCENT trial of sacituzumab govitecan versus standard chemotherapy in metastatic triple-negative breast cancer ﻿

Health-related Quality of Life in the Phase III LUME-Colon 1 Study: Comparison and Interpretation of Results From EORTC QLQ-C30 Analyses ﻿

Health-Related Quality of Life with Pembrolizumab in Patients with Locally Advanced or Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma: KEYNOTE-629 ﻿

Hepatic Rupture as the Initial Presentation of an EGFR-Mutated Lung Adenocarcinoma: A Case Report ﻿

HER2 and p95HER2 differentially regulate miRNA expression in MCF-7 breast cancer cells and downregulate MYB proteins through miR-221/222 and miR-503 ﻿

HER2 Copy Number and Resistance Mechanisms in Patients with HER2-positive Advanced Gastric Cancer Receiving Initial Trastuzumab-based Therapy in JACOB Trial ﻿

HER2DX genomic test in HER2-positive/hormone receptor-positive breast cancer treated with neoadjuvant trastuzumab and pertuzumab: A correlative analysis from the PerELISA trial ﻿

Hereditary Leiomyomatosis and Renal Cell Cancer Syndrome in Spain: Clinical and Genetic Characterization ﻿

HERTHENA-Lung01, a Phase II Trial of Patritumab Deruxtecan (HER3-DXd) in Epidermal Growth Factor Receptor–Mutated Non–Small-Cell Lung Cancer After Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and Platinum-Based Chemotherapy ﻿

HERTHENA-Lung01: a phase II study of patritumab deruxtecan (HER3-DXd) in previously treated metastatic EGFR-mutated NSCLC ﻿

Hierarchical chromatin organization detected by TADpole ﻿

High absolute lymphocyte counts are associated with longer overall survival in patients with metastatic breast cancer treated with eribulin—but not with treatment of physician’s choice—in the EMBRACE study ﻿

High levels of chromosomal aberrations negatively associate with benefit to checkpoint inhibition in NSCLC ﻿

High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER+ breast cancer ﻿

Highlights from ASCO-GI 2021 from EORTC Gastrointestinal tract cancer group ﻿

Hitting the brakes on autophagy for overcoming acquired resistance in triple negative breast cancer ﻿

HMGA1, Moonlighting Protein Function, and Cellular Real Estate: Location, Location, Location! ﻿

Homologous Recombination Deficiency Across Subtypes of Primary Breast Cancer ﻿

Coneix Scientia

Guies i ajudes

Directe a...

Coneix Scientia

Guies i ajudes

Directe a...

Health-related quality of life associated with trifluridine/tipiracil in heavily pretreated metastatic gastric cancer: results from TAGS

Health-related quality of life in patients with a germline BRCA mutation and metastatic pancreatic cancer receiving maintenance olaparib

Health-related quality of life in the phase III ASCENT trial of sacituzumab govitecan versus standard chemotherapy in metastatic triple-negative breast cancer

Health-related Quality of Life in the Phase III LUME-Colon 1 Study: Comparison and Interpretation of Results From EORTC QLQ-C30 Analyses

Health-Related Quality of Life with Pembrolizumab in Patients with Locally Advanced or Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma: KEYNOTE-629

Hepatic Rupture as the Initial Presentation of an EGFR-Mutated Lung Adenocarcinoma: A Case Report

HER2 and p95HER2 differentially regulate miRNA expression in MCF-7 breast cancer cells and downregulate MYB proteins through miR-221/222 and miR-503

HER2 Copy Number and Resistance Mechanisms in Patients with HER2-positive Advanced Gastric Cancer Receiving Initial Trastuzumab-based Therapy in JACOB Trial

HER2DX genomic test in HER2-positive/hormone receptor-positive breast cancer treated with neoadjuvant trastuzumab and pertuzumab: A correlative analysis from the PerELISA trial

Hereditary Leiomyomatosis and Renal Cell Cancer Syndrome in Spain: Clinical and Genetic Characterization

HERTHENA-Lung01, a Phase II Trial of Patritumab Deruxtecan (HER3-DXd) in Epidermal Growth Factor Receptor–Mutated Non–Small-Cell Lung Cancer After Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and Platinum-Based Chemotherapy

HERTHENA-Lung01: a phase II study of patritumab deruxtecan (HER3-DXd) in previously treated metastatic EGFR-mutated NSCLC

Hierarchical chromatin organization detected by TADpole

High absolute lymphocyte counts are associated with longer overall survival in patients with metastatic breast cancer treated with eribulin—but not with treatment of physician’s choice—in the EMBRACE study

High levels of chromosomal aberrations negatively associate with benefit to checkpoint inhibition in NSCLC

High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER+ breast cancer

Highlights from ASCO-GI 2021 from EORTC Gastrointestinal tract cancer group

Hitting the brakes on autophagy for overcoming acquired resistance in triple negative breast cancer

HMGA1, Moonlighting Protein Function, and Cellular Real Estate: Location, Location, Location!

Homologous Recombination Deficiency Across Subtypes of Primary Breast Cancer